Previous Patent Infringement Contentions and Expert Testimony May Inform the Scope of Subsequent Allegations

Jun 8, 2020

Reading Time : 3 min

In 2016, Oyster Optics, LLC (“Oyster”) brought patent infringement actions against Fujitsu Limited (“Fujitsu”), Fujitsu Network Communications, Inc. (FNC), Alcatel-Lucent USA, Inc. (ALU), and Cisco Systems, Inc. (“Cisco”) in the Eastern District of Texas, alleging infringement of U.S. Patent No. 7,620,327 (“the ’327 Patent”). The ’327 Patent is directed to transceiver cards for sending and receiving data over a fiber optic network, and Oyster’s allegations against Fujitsu and FNC were directed towards Fujitsu’s modulators and integrated receivers, among other products. Oyster’s actions against ALU and Cisco were based on their sales of products which contained Fujitsu modulators and receivers. The ALU and Cisco actions were eventually consolidated with Oyster’s action against FNC.

In 2018, Oyster settled its action against FNC, and entered into the Oyster/Fujitsu Agreement (“Agreement”). By the terms of the Agreement, Oyster agreed to release “FNC, Fujitsu, and their Affiliates” from claims of patent infringement of the ’327 Patent. Additionally, the Agreement extended Oyster’s release to FNC’s customers for claims of infringement of the ’327 Patent directed towards “Licensed Products,” a term defined by the Agreement as products “made, sold, imported, or distributed by FNC, [Fujitsu], or their Affiliates.” The definition of Licensed Products further clarified that it did not prevent Oyster from exercising its patent rights directed towards Licensed Products not substantially embodying the essential features of the ’327 Patent. The Agreement also granted Fujitsu, FNC, and their Affiliates a forward-looking license to the ’327 Patent.

As a result of the Agreement, ALU and Cisco moved for summary judgement, arguing that the Agreement released them—as customers of FNC/Fujitsu—of all claims of infringement directed to products containing Fujitsu modulators and receivers. The district court granted the motion, reasoning that the Agreement’s provision regarding Oyster’s ability to exercise its patent rights against products not substantially embodying the essential features of the ’327 Patent applied only to the forward-looking license and not to the release of infringement claims. The district court also held, in the alternative, that the Agreement released ALU and Cisco from liability because the accused ALU and Cisco products embodied the essential features of the ’327 Patent.

The Federal Circuit resolved the appeal on the basis of the district court’s alternative ruling. Hence, the primary question on appeal was whether the Fujitsu modulators and receivers incorporated into the accused ALU and Cisco products substantially embodied the essential features of the ’327 Patent. Oyster argued that the Fujitsu modulators and receivers did not substantially embody the essential features of the ’327 Patent because the claims of the ’327 Patent were directed to a transceiver card, requiring components in addition to a modulator and a receiver. Furthermore, Oyster contended that its allegations of infringement against Fujitsu and FNC directed to modulators and receivers were based only on indirect infringement. The Federal Circuit, however, upheld the district court’s holding that the accused ALU and Cisco products did indeed substantially embody the essential features of the ’327 Patent. The Federal Circuit reached this conclusion based on Oyster’s previous infringement contentions and expert testimony, which repeatedly alleged infringement of the ’327 Patent by the Fujitsu modulators and receivers. For example, Oyster specifically named the Fujitsu modulators and receivers as products accused of infringing the ’327 Patent in previous litigation, and Oyster’s expert gave testimony on Fujitsu modulators and receivers to the same effect.

Oyster Optics, LLC v. Alcatel-Lucent USA, Inc., 2019-1255, 2019-1257 (Fed. Cir. May 27, 2020).

Practice Tip: A party’s allegations, infringement contentions, and expert testimony regarding patent infringement may be used by a court to define or limit the scope of different allegations across related litigations. Thus, when litigating the same patent against different parties, practitioners should be cognizant that infringement allegations made in one proceeding may inform a court’s determinations in related or subsequent proceedings.

Share This Insight

Previous Entries

IP Newsflash

November 14, 2025

The Ninth Circuit recently reversed a district court’s decision to strike a plaintiff’s trade secret claims under the Defend Trade Secrets Act (DTSA) at the discovery stage. In doing so, the Ninth Circuit made clear that under the DTSA, whether a party defined their trade secret with sufficient particularity is a question of fact that generally does not lend itself to resolution in the absence of at least some discovery. This ruling contrasts with the California Uniform Trade Secrets Act (CUTSA), which requires a party to define their trade secrets with reasonable particularity before commencing discovery.

...

Read More

IP Newsflash

November 11, 2025

The Federal Circuit recently vacated a summary judgment ruling of invalidity, holding that the district court erred in applying preclusive effect to the Patent Trial and Appeal Board’s unpatentability findings regarding other claims in the same patent. In doing so, the Federal Circuit reiterated that issue preclusion does not apply where the prior factual determinations were made under a lower standard of proof.

...

Read More

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.